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Dual inhibition of the renin system by aliskiren and 
valsartan 
In 1898, Tigerstedt and Bergman discovered a 
powerful vasoconstrictor originating from the kidney, 
which they properly termed renin.1 This fundamental 
discovery started a mainstream of experimental and 
clinical research, leading up to the development of 
angiotensin-converting-enzyme (ACE) inhibitors, 
angiotensin-II type-1 receptor blockers (ARBs), and 
renin inhibitors. Aliskiren is the first orally active renin 
inhibitor that has progressed to phase III clinical trials.2
In today’s Lancet, Suzanne Oparil and colleagues 
report the first large-scale (more than 1700 patients) 
randomised study of dual renin-system inhibition 
with the maximum recommended daily doses 
of aliskiren (300 mg) and the ARB valsartan 
(320 mg).3 At 8 weeks, aliskiren plus valsartan 
lowered blood pressure significantly more than 
either monotherapy or placebo (p<0·0001). When 
measured by conventional sphygmomanometry, the 
placebo-corrected blood-pressure-lowering activity 
of the combination averaged 12·6 mm Hg systolic 
and 8·1 mm Hg diastolic. Combination therapy 
provided additional systolic/diastolic reductions of 
4·4/3·2 mm Hg and 4·2/2·5 mm Hg over aliskiren and 
valsartan monotherapy, respectively. Renin inhibitors 
do not lower blood pressure in normotensive indi-
viduals.2 An 8-h daytime ambulatory blood pressure 
of at least 90 mm Hg was therefore a prerequisite for 
entry in Oparil’s study. Only 45% of screened patients 
were randomised. The generalisability of these results 
is limited by the selective recruitment and the use of 
diastolic rather than systolic blood pressure as the 
main selection criterion and primary-efficacy variable.
More than 25 years ago, one of us reported for 
the first time escape of the inhibition of the renin 
system during long-term treatment with the ACE 
inhibitor captopril.4 ACE inhibitors, ARBs, and renin 
inhibitors interrupt the normal feedback suppression 
of renin secretion from the kidneys. The reactive rise in 
circulating active renin leads to greater generation of 
angiotensin I,2 which in turn increases the formation of 
angiotensin II via pathways dependent or independent 
of ACE. Non-ACE-dependent pathways of angiotensin 
generation, for instance via chymase5 or ACE,2,6 are 
upregulated during long-term ACE inhibition (figure). 
The increase in serum potassium also contributes to 
the increase in aldosterone secretion during chronic 
inhibition of the renin system.4 Renin inhibitors do 
not block renin-like enzymes, such as cathepsin D 
or tonins, which are present in the vascular wall and 
which release angiotensin I from angiotensinogen 
(figure). The idea of dual inhibition of the renin system 
has its rationale in limiting the escape during chronic 
inhibition of the renin system at a single step of the 
cascade. ARBs combined with ACE inhibitors shield the 
type-1 receptor against angiotensin II generated via 
non-ACE pathways. ACE inhibitors or ARBs, on top of 
renin inhibitors, protect against angiotensin generated 
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Figure: Renin-angiotensin-aldosterone system2
AT-R=angiotensin receptor. EP=endopeptidases. EC=endothelial cells. Black arrows show stimulation and red arrows 
show inhibition. Full lines represent major functional pathways and dotted lines show alternative pathways. 
β blockers, renin inhibitors, ACE inhibitors, and ARBs decrease activity of renin-angiotensin system (RAS). 
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via renin-like enzymes. Renin inhibitors combined with 
ACE inhibitors or ARBs inhibit plasma renin activity 
even in the presence of a reactive rise in renin. In line 
with this concept, in Oparil and colleagues’ study, 
the combination of aliskiren with valsartan reduced 
plasma renin activity by 44%, despite a nine-fold 
increase in the renin concentration.
Oparil and colleagues report that the rates of adverse 
events and laboratory abnormalities were similar in 
all groups. However, they note that the proportion of 
patients with a transient increase of serum potassium 
above 5·5 mmol/L at any time post-baseline was 
higher in the combination group (4%) than in the 
aliskiren (2%) and valsartan monotherapy groups (2%) 
or in the placebo group (3%).
Hyperkalaemia can result in severe complications, 
such as paralysis, arrhythmias, and cardiac arrest. In 
patients with hyperkalaemia (>6·0 mmol/L) admitted 
to a teaching hospital, drug treatment in general 
and ACE inhibitors in particular were contributing 
factors in 63% and 15% of cases, respectively.7 Severe 
hyperkalaemia often remains unrecognised,8 with few 
symptoms prior to cardiac arrest.
Phase III trials of aliskiren with intermediate 
endpoints are in progress in high-risk patients with 
left ventricular hypertrophy, heart failure, or renal 
dysfunction.2 Because of the expected differences in 
blood-pressure between the groups randomised in 
these trials, interpretation will not be easy. No new 
class of antihypertensive agents should make it to 
routine use without hard outcome data. That necessity 
applies even more to dual inhibition of the renin 
system, which exposes patients to hyperkalaemia 
and renal insufficiency.7,8 Trials of the combination 
of ARBs with ACE inhibitors in patients with heart 
failure,9 kidney disease,10 or high-risk hypertension11 
are complete9,10 or close to publication.11 In terms 
of blood-pressure reduction, Oparil and colleagues’ 
trial supports the concept of dual renin inhibition, 
with a renin inhibitor and an ARB. However, the 
additional blood-pressure reduction, over and beyond 
that provided by the single components, was not 
as large as might be expected from combining any 
two antihypertensive agents from different classes. 
One wonders therefore why Oparil opted to combine 
aliskiren with valsartan, rather than with a diuretic 
or a calcium-channel blocker, as recommended by 
current guidelines.12 Such agents decrease serum 
potassium, and counteract the increase in serum 
potassium on renin-system inhibitors. In the end, 
dual renin inhibition might find a niche in selected 
hypertensive patients at high risk with associated 
conditions9–11 or in treatment-resistant hypertension. 
However, because of the potential life-threatening 
side-effects,7,8 which require biochemical monitoring, 
this concept of treatment is unlikely to make it to 
general practice or even to primary prevention in 
specialist care.
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